Your browser doesn't support javascript.
loading
Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19.
Tamura, Ryo; Irie, Kei; Nakagawa, Atsushi; Muroi, Hirohito; Eto, Masaaki; Ikesue, Hiroaki; Muroi, Nobuyuki; Fukushima, Shoji; Tomii, Keisuke; Hashida, Tohru.
Afiliação
  • Tamura R; Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Irie K; Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Nakagawa A; Faculty of Pharmaceutical Science, Kobe Gakuin University, Kobe, Japan.
  • Muroi H; Department of Respiratory Medicine, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Eto M; Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Ikesue H; Department of Clinical Laboratory, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Muroi N; Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Fukushima S; Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Tomii K; Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Hashida T; Faculty of Pharmaceutical Science, Kobe Gakuin University, Kobe, Japan.
CPT Pharmacometrics Syst Pharmacol ; 12(4): 513-521, 2023 04.
Article em En | MEDLINE | ID: mdl-36798006

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão